Table 4. Remission after switching to a different biologic therapy in the GAN registry 2011 – 2024.
| Item | Anti-IgE – anti-IL5 | Anti-IgE – anti-IL4R | Anti-IL5 – anti-IL5R | Anti-IL5 – anti-IL4R | Anti-IL5R – anti-IL4R | |
|---|---|---|---|---|---|---|
| Exacerbation last 12 months at post visit | N | 8 | 17 | 42 | 24 | 34 |
| None | 6 (75.0%) | 12 (70.6%) | 28 (66.7%) | 15 (62.5%) | 22 (64.7%) | |
| At least 1 | 2 (25.0%) | 5 (29.4%) | 14 (33.3%) | 9 (37.5%) | 12 (35.3%) | |
| Maintenance OCS at post visit | N | 8 | 17 | 42 | 24 | 34 |
| No | 3 (37.5%) | 16 (94.1%) | 29 (69.0%) | 22 (91.7%) | 28 (82.4%) | |
| Yes | 5 (62.5%) | 1 (5.9%) | 13 (31.0%) | 2 (8.3%) | 6 (17.6%) | |
| ACT points at post visit | N | 8 | 17 | 42 | 24 | 34 |
| < 20 ACT points | 2 (25.0%) | 9 (52.9%) | 17 (40.5%) | 10 (41.7%) | 17 (50.0%) | |
| ≥ 20 ACT points | 6 (75.0%) | 8 (47.1%) | 25 (59.5%) | 14 (58.3%) | 17 (50.0%) | |
| Difference to baseline in FEV1 [L] | N | 8 | 17 | 42 | 24 | 34 |
| < 0.1 L | 5 (62.5%) | 8 (47.1%) | 23 (62.2%) | 13 (59.1%) | 19 (63.3%) | |
| ≥ 0.1 L | 3 (37.5%) | 9 (52.9%) | 14 (37.8%) | 9 (40.9%) | 11 (36.7%) | |
| Missing values | – | – | 5 | 2 | 4 | |
| Remission I | N | 8 | 17 | 42 | 24 | 34 |
| No remission | 6 (75.0%) | 12 (70.6%) | 26 (61.9%) | 13 (54.2%) | 23 (67.6%) | |
| Remission | 2 (25.0%) | 5 (29.4%) | 16 (38.1%) | 11 (45.8%) | 11 (32.4%) | |
| Remission II | N | 8 | 17 | 42 | 24 | 34 |
| No remission | 7 (87.5%) | 16 (94.1%) | 33 (89.2%) | 17 (77.3%) | 28 (93.3%) | |
| Remission | 1 (12.5%) | 1 (5.9%) | 4 (10.8%) | 5 (22.7%) | 2 (6.7%) | |
| Missing values | – | – | 5 | 2 | 4 |
Remission I: No exacerbations in the previous 12 months, no OCS use; and ACT ≥ 20 points. Remission II: No exacerbations in the previous 12 months, no OCS use, ACT ≥ 20 points; and FEV1 improvement of ≥ 100 mL. OCS = oral corticosteroids; ACT = asthma control test; FEV1 = forced expiratory volume in 1 second; L = liters; GAN = German Asthma Net.